Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

E. John Wherry, director of Penn's Colton Center for Autoimmunity, spoke with the Inquirer about the future of immunology ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...

India’s cancer care sector, valued at Rs 1.25 lakh crore and growing 10–12% annually, is attracting significant private ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

And that's a good thing. Oxidants can damage the structure and function of the chemicals in your body critical to life—like ...